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Abstract 
Introduction: The isoniazid-resistant TB poses a threat to TB control efforts. Zimbabwe, one of the high TB burden countries, has not explored 
the burden of isoniazid resistant TB. Hence among all bacteriologically-confirmed TB patients diagnosed in Bulawayo City during March 2017 
and December 2018, we aimed to assess the proportion with isoniazid resistant TB and associated factors. Also, we aimed to describe the TB 
treatment outcomes.  
Methodology: A cohort study involving routinely collected data by the National TB Reference Laboratory (NTBRL) in Bulawayo City and 
National TB programme of Zimbabwe. The percentage with 95% confidence interval (CI) was used to express the proportion with isoniazid-
resistant TB. The modified Poisson regression was used to assess the association of demographic and clinical characteristics with isoniazid 
mono-resistant TB.  
Results: Of 2160 bacteriologically-confirmed TB patients, 1612 (74.6%) had their sputum received at the NTBRL and 743 (46.1%) had culture 
growth. Among those with culture growth, 34 (4.6%, 95% CI: 3.5-6.7) had isoniazid mono-resistant TB, 25 (3.3%, 95% CI: 2.2-4.9) had MDR-
TB. Thus, 59 (7.9%, 95% CI: 6.1-10.1) had isoniazid-resistant TB. Children < 15 years had a higher prevalence of isoniazid mono-resistant 
TB (aPR= 3.93; 95% CI: 1.24-12.45). Among those with rifampicin sensitive TB, patients with isoniazid-sensitive TB had higher favourable 
treatment outcomes compared to those with isoniazid-resistant TB (86.3% versus 75.5%, p = 0.039). 
Conclusions: The prevalence of isoniazid-resistant TB was low compared to neighbouring countries with high burden of TB-HIV. However, 
Zimbabwe should consider reviewing treatment guidelines for isoniazid mono-resistant TB due to the observed poor treatment outcomes. 
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Introduction 
Tuberculosis (TB) remains a major public health 
problem globally, with an estimated 10 million incident 
cases and an estimated 1.2 million deaths in 2018 [1]. 
Despite a noticeable decline in the TB burden over the 
last two decades, the emergence of drug-resistant TB 
has posed a threat to TB control efforts. In 2013, the 
World Health Organization (WHO) described 
resistance to TB drugs as a ‘ticking time bomb’ among 
called for ‘visionary political leadership’ to mitigate 
this threat [2].  
Isoniazid is an important, effective and cheap first-
line anti-TB drug with low rates of adverse events [3]. 
The drug provides a high initial kill at the start of active 
TB treatment compared to other first-line TB drugs 
used in standard anti-TB treatment regimen 
recommended by WHO [4]. Isoniazid is also used as 
chemoprophylaxis against TB in selected high-risk 
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groups like people living with HIV (PLHIV) and those 
with latent TB infection (LTBI) [5]. 
A recent systematic review reported that resistance 
to isoniazid could make the standard anti-TB treatment 
regimen weak and eventually lead to higher rates of 
unfavourable treatment outcomes [6]. Therefore, WHO 
recommended the addition of fluoroquinolones in the 
regimen for managing TB patients with isoniazid 
resistance [7]. However, countries were directed to 
adopt an appropriate regimen for TB patients with 
isoniazid resistance based on the existing prevalence of 
isoniazid resistance, availability of culture and drug 
susceptibility testing (CDST) and prevalence of 
fluoroquinolone resistance [7].  
In 2011, a systematic review estimated the global 
prevalence of isoniazid resistance to be 13.9% among 
TB patients, with exclusion of Eastern Europe where 
the prevalence was 44.9% [8]. However, this estimate 
was unreliable as data were available only from 106 
countries. During the review, Botswana and South 
Africa were the only two high HIV burden countries 
that had information on isoniazid resistance and both 
showed an increasing trend [9, 10]. Thus, the review 
recommended for future research to assess the 
prevalence of isoniazid resistance in high HIV burden 
countries [11]. 
Zimbabwe is a high HIV burden country with a 
triple burden of TB, TB/HIV and multi-drug resistant 
TB (MDR-TB). In 2017, there were an estimated 
30,000 new TB patients and 4,600 deaths due to TB [1]. 
Adhering to WHO recommendations for surveillance of 
anti-TB drug resistance, the national TB programme 
(NTP) of Zimbabwe carried out the first drug resistance 
survey in the year 2016. However, the survey failed to 
estimate the prevalence of isoniazid resistance among 
TB patients as CDST was done only among those with 
rifampicin resistance.  
The prevalence of isoniazid resistance could not be 
estimated under routine programme, as the NTP 
recommended CDST only among rifampicin-resistant 
TB patients. However, in March 2017, the diagnostic 
algorithm was revised and CDST was offered to all 
bacteriologically-confirmed TB patients. Although the 
algorithm was revised again in September 2017 with the 
recommendation of CDST reserved for rifampicin-
resistant TB patients, the change was partially 
disseminated to health care providers in the Bulawayo 
metropolitan province of Zimbabwe. Thus, the health 
workers from peripheral health facilities of the province 
continued to send sputum samples of bacteriologically-
confirmed TB patients for CDST at the National 
tuberculosis reference laboratory (NTBRL). This 
provided a unique opportunity to estimate the burden of 
isoniazid resistance under routine programmatic 
settings.  
We therefore set out to determine, among 
bacteriologically confirmed TB patients diagnosed 
between March -2017 and December-2018 in the in 
Bulawayo metropolitan province, the number and 
proportion; 1) undergoing first-line DST 2) showing 
bacterial growth on culture media, among those who 
underwent CDST 3) with isoniazid resistance among 
those with growth on culture and associated factors. 
Also, to compare the programmatic TB treatment 
outcomes among the rifampicin sensitive TB patient 




We conducted a cohort study using secondary data 
routinely collected by the NTBRL in Bulawayo and 




Zimbabwe is a landlocked country in southern 
Africa with a total population of 16.5 million [12]. The 
country is divided into ten provinces of which two of 
them are metropolitan. The majority (67%) of the 
population resides in rural areas and an estimated 72% 
of the population is below the poverty line. HIV and TB 
care services are offered free of charge and are 
integrated with general health services. 
 
Specific Setting 
The diagnosis of TB, first-line CDST and treatment 
of tuberculosis in the Bulawayo metropolitan province 
of Zimbabwe are described below. 
 
Diagnosis of bacteriologically confirmed TB 
The presumptive pulmonary TB patients identified 
using the WHO symptom TB screening tool (current 
cough, fever, haemoptysis, weight loss and night 
sweats) at health facilities are offered Xpert MTB/Rif 
assay (Cepheid, Sunnyvale, CA, USA) for diagnosis of 
TB. Two spot sputum samples (two hours apart) are 
collected at the facility and are transferred to the 
GeneXpert site. One of the two sputum samples is 
subjected to Xpert MTB/Rif assay. If the sample is 
positive for MTB, the second sample is sent to NTBRL 
for CDST. Health facilities also send extra-pulmonary 
specimens for bacteriological confirmation of TB. 
These specimens are divided into two parts and one part 
is subjected to Xpert MTB/Rif assay. If MTB is 
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detected, the other part of the specimen is sent to 
NTBRL for first-line DST.  
At the GeneXpert site, the demographic details of 
the patients, assay result, information on referral for 
treatment and details of dispatch of the second sputum 
to NTBRL are documented in the “laboratory register” 
by the lab technician. 
 
First-line drug CDST at NTBRL 
Samples at the NTBRL are decontaminated using 
the modified Petroff method and inoculated on both 
MGIT (liquid) (Becton Dickinson and Co, New Jersey, 
USA) and Lowenstein-Jensen (solid) culture media. 
The procedure of decontamination, inoculation and 
culture are in line with the Stop TB Partnership 
mycobacteriology laboratory manual [13]. In the 
samples which show growth, identification of the 
bacteria is made using the SD Bioline kit (Standard 
Diagnostics, Inc., Korea) and the isolate is subjected to 
first-line phenotypic DST. The DST is conducted at a 
critical concentration of isoniazid at 0.1µg/mL, 
rifampicin at 1.0µg/mL, ethambutol at 5.0µg/mL and 
streptomycin at 1.0µg/mL [14].  
The external quality assurance panels from the 
supranational reference laboratory assess the quality of 
CDST at the NTBRL. The NTBRL was graded 
excellent for quality during the study reference period. 
The details of samples reaching the NTBRL and the 
CDST results are documented in the electronic CDST 
database maintained at the NTBRL. 
 
Tuberculosis treatment 
The GeneXpert site informs the result of Xpert 
MTB/Rif assay to health facilities for patient-tracking 
and initiation of anti-TB treatment. In the health 
facilities, all the rifampicin-sensitive TB patients are 
initiated by the nurse or physician on standard anti-
tuberculosis treatment as recommended by the NTP 
[15]. 
All the TB patients receive two months of intensive 
phase (2HRZE: H = Isoniazid, R = Rifampicin, P = 
Pyrazinamide, E = Ethambutol) and four months of 
continuation phase (4HR). Fixed-dose combination 
(FDC) drugs of HRZE (4FDC) and HR (2FDC) are 
provided. The number of tablets to be consumed ranges 
from two to five based on the weight of the patient. The 
staff nurse provides directly observed treatment. 
Fluoroquinolone based regimens for TB patients with 
isoniazid resistance is not practiced in Zimbabwe. The 
healthcare provider ascertains the treatment outcomes 
of the TB patients as per NTP guidelines [15]. 
At health facilities, the socio-demographic, clinical 
and treatment outcome details of TB patients initiated 
on treatment are documented in the TB register 
maintained by the staff nurse.  
 
Study Population 
We included all bacteriologically-confirmed TB 
patients diagnosed between March 2017 and December 
2018 in the Bulawayo metropolitan province of 
Zimbabwe.  
 
Data Variables, sources of data and data collection 
The data variables including patient names, age, 
gender, type of TB, site of TB and Xpert assay results 
were obtained from the Gene Xpert site ‘laboratory 
registers’ between April and May-2019 using a 
customized Excel database populated by laboratory 
technicians.  
This data was later merged with data from the 
NTBRL database on receipt of samples at the NTBRL, 
culture growth and CDST results using patient names, 
age, gender and the Gene Xpert site. Details on HIV 
status, antiretroviral therapy (ART) status and TB 
treatment outcomes were later traced from each 
patient's respective DOT health facility and updated 
into the database.  
 
Data entry and analysis 
The data entered in Microsoft Excel was exported 
for analysis using Stata (version 15.0 STATA 
Corporation, USA). Socio-demographic and clinical 
characteristics of participants were summarized using 
percentages. The Chi Square test was used to compare 
the socio-demographic and clinical characteristics of 
bacteriologically confirmed TB patients with- and 
without- receipt of samples at the NTBRL. Similar 
comparison was done among patients with receipt of 
samples at NTBRL with- and without- culture growth. 
Multivariate-adjusted prevalence ratios and their 
respective 95% confidence intervals were calculated 
using a generalized linear regression model with a log-
binomial link to determine factors associated with 
having isoniazid mono-resistance. The TB treatment 
outcomes of rifampicin sensitive TB patients were 
compared between those with and without isoniazid 
resistance using a Chi Square test. P-values were set 5% 
levels of significance.  
 
Ethics 
The ethics approval for the study was obtained from 
the Ethics Advisory Group of the International Union 
Against Tuberculosis and Lung Disease, Paris, France 
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(40/19) and the Medical Research Council of 
Zimbabwe (MRCZ/E/255). Permission to access data 




In Bulawayo province during the study reference 
period, 2160 individuals were diagnosed with 
bacteriologically-confirmed TB patients. Of the total, 
the median age was 36 (Interquartile range, 29-45) 
years and 1314 (60.8%) were males. Of the 2160 
patients, 2031 (94.0%) had new TB, 2017 (93.4%) had 
pulmonary TB and 153 (7.1%) had rifampicin 
resistance detected on Xpert MTB/Rif assay. Of the 
1346 (62.3%) with recorded HIV status, 976 (72.5%) 
were HIV co-infected, of whom, 741 (75.9%) were 
receiving ART (Table 1.)  
Of all the bacteriologically confirmed TB patients, 
1612 (74.6%) had their sputum specimen sent to the 
NTBRL and of these, 743 (46.1%) had culture growths. 
In those with culture growths, 34 (4.6%, 95% CI: 3.5%-
6.7%) had isoniazid mono-resistance and 25 (3.3%, 
95%CI: 2.2%-4.9%) had multidrug resistant TB. 
Overall, 59 (7.9%, 95% CI: 6.1%-10.1%) had isoniazid 
resistance among those with culture growth (Figure 1). 
On comparison of baseline demographic and 
clinical characteristics of bacteriologically confirmed 
TB patients with- and without- receipt of samples at the 
NTBRL, the groups statistically differed in distribution 
of ‘site of TB’ (p value = 0.013) and ‘HIV/ART status’ 
(p < 0.001) (Supplementary Table 1). 
On comparison of baseline demographic and 
clinical characteristics of those with- and without- 
culture growth among those with sample received at 
NTBRL, age (p = 0.005), gender (p < 0.001), type of 
TB (p < 0.001), site of TB (p < 0.001) and ‘HIV/ART 
status’ (p < 0.001) differed statistically across the two 
groups (Supplementary Table 2). 
Table 1. Socio-demographic and clinical characteristics of 
bacteriologically-confirmed TB patients in Bulawayo City, 
Zimbabwe (March 2017-December 2018). 
Variable n (%) 
Gender  
Male 1,314 (60.8) 
Female 846 (39.2) 
Age (in years)  
< 15 45 (2.1) 
15-24 267 (12.4) 
25-34 609 (28.2) 
35-44 603 (27.9) 
45-54 304 (14.1) 
55+ 228 (10.6) 
Not recorded 104 (4.8) 
Type of TB patient  
New 2,031 (94.0) 
Retreatment 67 (3.1) 
Not recorded 62 (2.9) 
Site of TB  
Pulmonary TB 2,017 (93.4) 
Extra-pulmonary TB 9 (< 1) 
Not recorded 134 (6.2) 
Genotypic rifampicin resistance pattern  
Rif -ve 1,998 (92.5) 
Rif +ve 153 (7.1) 
Rif Indeterminate 9 (< 1) 
HIV status:  
Negative 370 (17.1) 
Positive 976 (45.2) 
Not recorded 814 (37.7) 
On ART  
Yes 741 (75.9) 
Not recorded 235 (24.1) 
Total 2,160 (100) 
Rif +ve = Rifampicin resistance detected, Rif -ve = Rifampicin sensitive; 
HIV = Human immunodeficiency virus; ART = Antiretroviral therapy. 
Figure 1. Flow chart of specimen submission to the National TB 
Reference Laboratory, results of CDST and isoniazid resistance 
among all bacteriologically-confirmed TB patients in Bulawayo, 
Zimbabwe (March 2017 – December 2018). 
* This includes 67 who were Rif resistant; MTB = Mycobacterium 
tuberculosis; Rif = Rifampicin; NTBRL = National TB Reference 
laboratory; MOTT- Mycobacterium Other Than Tuberculosis; CDST- 
Culture and Drug Susceptibility Testing. 
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The demographic and clinical characteristics 
associated with isoniazid mono-resistance among those 
with culture growth and rifampicin sensitive TB is 
shown in Table 2. Those with age < 15 years had higher 
(aPR = 3.93; 95% CI: 1.24-12.45) prevalence of 
isoniazid mono-resistance compared to those who were 
25-34 years old. 
Comparison of TB treatment outcomes between 
those with- and without- isoniazid resistance among 
bacteriologically confirmed TB patients with 
rifampicin sensitive TB are shown in Table 3. Of the 
610 patients with rifampicin sensitive TB, 604 (99%) 
were started and notified on TB treatment. Among these 
notified TB patients, those with isoniazid resistant TB 
had poorer TB treatment outcomes in comparison to 
those with isoniazid sensitive TB (25 (73.5%) versus 
492 (86.3%), p = 0.039). Deaths were observed in 5 
(14.7%) of the isoniazid resistant TB patients and 37 
(6.5%) of isoniazid sensitive TB patients (p = 0.078). 
 
Discussion 
This is the first study from Zimbabwe assessing the 
extent of isoniazid resistance under the routine national 
TB programme. There were some findings of note. 
First, about three-quarters of bacteriologically-
confirmed TB patients detected on Xpert MTB/Rif 
assay, had their sputum specimens received at the 
NTBRL for CDST. Second, only half of specimens 
received at the NTBRL had a culture growth despite the 
culture contamination rate being within the 
recommended limits. Third, one in thirteen of patients 
with a culture growth had any isoniazid resistance 
whilst approximately one in twenty had isoniazid 
mono-resistance (resistant to isoniazid and sensitive to 
rifampicin). The prevalence of isoniazid resistance and 
isoniazid mono-resistance was low. Only children < 15 
years had higher prevalence of isoniazid resistance 
among those with rifampicin sensitive TB. Lastly, 
among patients with rifampicin sensitive TB, TB 
treatment outcomes were poorer among those with 
isoniazid resistant TB compared to those with isoniazid 
sensitive TB. 
Our study had a number of strengths which included 
use of routine programmatic data, hence reflecting the 
ground realities of the national TB programme. Second, 
about three-quarters of the bacteriologically-confirmed 
TB patients underwent CDST, regardless of rifampicin 
resistance pattern and hence enabling estimation of INH 
Table 2. Characteristics associated with isoniazid mono-resistance among bacteriologically-confirmed TB patients with culture growth among 
specimens received at the NTBRL from Bulawayo City, Zimbabwe (March 2017-December 2018). 
Variable N INH mono-resistanceǂ, n (%) PR (95% CI) aPR (95% CI)₸ 
Total 610 34 (5.6) - - 
Gender     
Male 405 23 (5.7) Reference Reference 
Female 205 11 (5.4) 0.94 (0.47-1.90) 1.05 (0.52-2.12) 
Age category (in years):     
< 15 12 3 (25.0) 4.07 (1.29-12.86) 3.93 (1.24-12.45) 
15-24 93 0 (0) -  
25-34 163 10 (6.1) Reference Reference 
35-44 176 15 (8.5) 1.39 (0.64-3.00) 1.41 (0.65-3.06) 
45-54 85 3 (3.5) 0.58 (0.16-2.03) 0.58 (0.17-2.06) 
55+ 57 2 (3.5) 0.57 (0.13-2.53) 0.54 (0.12-2.44) 
Not recorded 24 1 (4.2) 0.68 (0.09-5.07) 0.64 (0.09-4.80) 
Type of TB patient:     
New 575 34 (5.9) Reference Reference 
Retreatment 32 0 (0) - - 
Not recorded 3 0 (0) - - 
Site of TB     
Pulmonary TB 594 34 (5.7) Reference Reference 
Extra-pulmonary TB 2 0 (0) - - 
Not recorded 14 0 (0) - - 
HIV & ART status     
HIV-ve 149 8 (5.4) Reference Reference 
HIV +ve, on ART 260 13 (5.0) 0.93 (0.40-2.19) 0.74 (0.31-1.76) 
HIV +ve, ART status unknown 60 2 (3.3) 0.62 (0.14-2.84) 0.48 (0.11-2.21) 
HIV status unknown 141 11 (7.8) 1.45 (0.60-3.51) 1.20 (0.51-2.84) 
NTBRL = National TB Reference Laboratory; INH = Isoniazid; PR = Prevalence Ratio; APR = multivariate-adjusted Prevalence Ratio; CI = Confidence Interval; 
TB = Tuberculosis; HIV = Human Immunodeficiency Virus; HIV +ve = HIV positive; HIV-ve = HIV negative; ART = antiretroviral therapy; ǂ Isoniazid mono-
resistance- Resistant to isoniazid but sensitive to rifampicin; ₸ Log binomial model with all the exposure variables included. 
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prevalence particularly among those with rifampicin 
sensitive TB patients. Third, we adhered to the 
Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines for reporting 
observational studies [16]. Our study was not without 
limitations. First, half of the bacteriologically 
confirmed cases with sputum samples received at the 
NTBRL had no culture growth and there were also 
differences in the distribution of patient characteristics 
between specimens with- and without- culture growth 
hence limiting inference of study findings. Second, 
there were also missing data for key study variables 
such as type of patient, site of TB and treatment 
outcomes of TB. 
There are a number of reasons for gaps in receipt of 
sputum samples for CDST. Whilst it is recommended 
to collect two spot sputum samples, two hours apart for 
all presumptive TB patients, often only one sample is 
collected. The second sample is collected only among 
those detected with MTB upon following them up for 
treatment initiation in the field. Thus, the field workers 
fail to collect the samples among the patients lost-to 
follow-up prior to treatment. Also, frequent changes in 
guidelines on CDST and lack of communication to 
Gene Xpert sites could be other potential reasons for 
low rate of receipt of samples at the NTBRL. 
The observed poor culture growth may be due to the 
decontamination process prior culture which might kill 
viable bacilli. Furthermore, there may have been a high 
proportion of salivary specimens which have been 
shown to yield culture negative results despite MTB 
being detected on Xpert assay [17]. The Xpert assay 
may also detect DNA from dead bacilli which will not 
show growth on culture media [18]. The volume of 
sputum submitted may have also been lower than the 
recommended 3 to 5 mL and hence affecting sputum 
quality. It is also plausible that the follow-up sputum 
that was submitted to the NTBRL among those with no 
culture growth were collected after the patients had 
been initiated on TB treatment. The mycobacterium 
growth rate has been shown to decline over time after 
commencing first-line anti-TB treatment when 
compared with Xpert MTB/RIF assay results [19,20].  
The prevalence of isoniazid resistance observed in 
our study was lower compared to the 7.3% reported in 
other settings with high HIV prevalence and also 
significantly lower than the global prevalence of 13.9% 
and 44.9% reported in Eastern Europe [8]. Other studies 
have reported increases in isoniazid resistance in high 
HIV burden countries potentially due to scale-up of 
isoniazid preventive therapy (IPT) among PLHIV [9]. 
Zimbabwe has shown low rates despite high IPT 
coverage rates among PLHIV since the inception of IPT 
in ART care settings from 2011 onwards [21]. 
Although, IPT was scaled up there might be a lag time 
delay for developing the isoniazid resistance and 
circulation of strains with resistance among TB 
patients. Thus, there is need for monitoring the trends 
in proportion with isoniazid resistance over the coming 
years. This is by either implementing routine screening 
of INH resistance in the programme using routinely 
collected data for all bacteriologically confirmed TB 
patients or through conducting drug resistant surveys 
frequently. 
Of note was that isoniazid resistance was 
predominantly higher among children < 15 years old 
and those who presented with new TB. The previous 
studies have not reported such high rates among 
children [22]. The reasons for the high rate seen among 
children in the current study are not known. However, 
it is cause for concern as children are most likely to have 
primary infection from adult contacts indicating the 
active circulation of isoniazid resistant TB strains. 
Thus, the future studies need to re-assess the association 
Table 3. TB treatment outcomes among bacteriologically-confirmed TB patients with rifampicin sensitive TB stratified by isoniazid 
susceptibility pattern from Bulawayo City, Zimbabwe, (March 2017 – December 2018). 
TB treatment outcome Total 
INH  resistance status 
P-value ǂ Resistance Sensitive 
n (%) n (%) n (%) 
Total 604 (100) 34 (100) 570 (100)  
Treatment Success 517 (85.6) 25 (73.5) 492 (86.3) 0.039 
Cured 477 (80.0) 24 (70.6) 453 (79.5) 0.217 
Treatment completed 40 (6.6) 1 (2.9) 39 (6.8) 0.718 
Adverse outcome 87 (14.4) 9 (26.5) 78 (13.7) 0.039 
Died 42 (7.0) 5 (14.7) 37 (6.5) 0.078 
Failure 4 (< 1) 0 (0) 4 (< 1) - 
LTFU 23 (3.8) 1 (2.9) 22 (3.9) 0.999 
Not evaluated 18 (3.0) 3 (8.8) 15 (2.6) 0.074 
TB = Tuberculosis; INH = Isoniazid; LTFU = loss to follow-up; ǂ All p-values were determined using the Fischer's Exact test excluding the p-value for 
comparisons for the proportions with “cured TB” and those with “TB treatment success” or “adverse outcome” where the Chi Square test was used; ₸6 patients 
were excluded in this analysis since they were not notified on TB treatment in Bulawayo City despite being diagnosed with TB. 
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and if such association exists, the studies have to 
explore the potential reasons for such association.  
Similar to evidence from previous studies, the 
current study also showed poor treatment outcomes 
among rifampicin sensitive TB patients with isoniazid 
resistance compared to those without resistance [9,22] 
though there was no statistically significant difference 
between the two groups in terms of death rates. This 
might be due to lower sample size for comparing the 
treatment outcomes.  
The study has a few implications and 
recommendations. With poor treatment outcomes 
among isoniazid resistant TB patients, there is need for 
identifying such patients for provision of individualized 
regimens to improve treatment outcomes. The existing 
gaps and deficiencies in CDST for assessing isoniazid 
resistance has to be fixed. The recommended two spot 
sputum samples have to be collected on presentation of 
presumptive TB patients. The register with details on 
dispatch of the second sample for CDST and results of 
CDST has to be maintained for all the patients with 
MTB detected on Xpert assay. This will enable the 
programme managers to monitor the activity. There is 
need for monitoring of sputum quantity and quality 
among sputum samples submitted to the NTBRL for 
CDST in order to improve the proportion of samples 
with successful culture growth [23].  
Alternatively, the point of care genotypic test like 
Abbott RealTime MTB RIF/INH Resistance (Abbott-
RIF/INH) or whole genome sequencing (WGS) can be 
adopted for detection of INH resistance. The point-of-
care tests will provide the results on isoniazid results 
instantly during diagnosis of TB and can aid in selecting 
appropriate treatment regimens. The genotypic tests are 
better options in high HIV burden settings with 
paucibacillary TB as large numbers of samples 
subjected to CDST fail to show culture growth and 
eventually go unassessed for isoniazid resistance.  
With poor treatment outcomes among isoniazid TB 
patients, there is need for adopting a six month regimen 
course composed of rifampicin (R), ethambutol (E), 
pyrazinamide (Z) and levofloxacin (Lfx) (accronymed 
Hr-TB) as per WHO guidelines [7]. However, this will 
require allocation of additional resources and training 
of existing staff on the new regimen.  
 
Conclusion 
The prevalence of isoniazid resistant TB was low 
compared to neighbouring countries with high burden 
of TB-HIV. However, Zimbabwe should consider 
reviewing treatment guidelines for isoniazid mono-
resistant TB due to the observed poorer outcomes. 
Further investigations should be done to establish the 
reason why the half of the bacteriologically confirmed 
samples failed to grow on culture media. There is also 
need to identify reasons why a quarter of samples were 
not received at the culture laboratory since it might be 
affecting even the rifampicin resistant cases a well. 
Lastly the overall adverse treatment outcomes among 
those with isoniazid resistant TB add to the body of 
literature which advocate for a change in the standard 
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Annex – Supplementary Items 
 
Supplementary Table 1. Comparison of demographic and clinical characteristics with and without receipt sample at the NTBRL for CDST 
among bacteriologically-confirmed TB patients in Bulawayo City, Zimbabwe (March 2017-December 2018). 
Variable Receipt of sample at NTBRL, n (%) P-value No Yes 
Total 548 (100) 1609 (100)  
Gender    
Male 332 (60.6) 982 (60.9) 0.89 
Female 216 (39.4) 630 (39.1)  
Age category (in years):    
< 15 9 (1.6) 36 (2.2) 0.532 
15-24 65 (11.9) 202 (12.5)  
25-34 172 (31.4) 437 (27.1)  
35-44 150 (27.4) 453 (28.1)  
45-54 75 (13.7) 229 (14.2)  
55+ 50 (9.1) 178 (11.0)  
Not recorded 27 (4.9) 77 (4.8)  
Type of TB patient:    
New 526 (96.0) 1505 (93.4) 0.067 
Retreatment 13 (2.4) 54 (3.4)  
Not recorded 9 (1.6) 53 (3.3)  
Site of TB    
Pulmonary TB 523 (95.4) 1494 (92.7) 0.013 
Extra-pulmonary TB 4 (< 1) 5 (< 1)  
Not recorded 21 (3.8) 113 (7.0)  
Genotypic rifampicin resistance pattern    
Rif -ve 512 (93.4) 1,486 (92.2) 0.170 
Rif +ve 32 (5.8) 121 (7.5)  
Rif Indeterminate 4 (< 1) 5 (< 1)  
HIV and ART status    
HIV-ve 108 (19.7) 262 (16.3) < 0.001 
HIV +ve, on ART 215 (39.2) 526 (32.6)  
HIV +ve, ART status unknown 57 (10.4) 178 (11.0)  
HIV status unknown 168 (30.7) 646 (40.1)  
TB = Tuberculosis; NTBRL = National Tuberculosis Reference Laboratory; CDST = Culture and Drug Susceptibility Test; Rif +ve = Rifampicin resistance 
detected, Rif -ve = Rifampicin sensitive; HIV = Human immunodeficiency virus; ART = Antiretroviral therapy. 
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Supplementary Table 2. Comparison of demographic and clinical characteristics with and without culture growth on CDST among 
bacteriologically-confirmed TB patients in Bulawayo City, Zimbabwe (March 2017-December 2018). 
Variable N Culture growth, n (%) P-value No Yes 
Total 1,612 869 (100) 743 (100)  
Gender     
Male 982 493 (56.7) 489 (65.8) < 0.001 
Female 630 376 (43.3) 254 (34.2)  
Age category (in years):     
< 15 36 23 (2.7) 13 (1.75) 0.005 
15-24 202 87 (10.0) 115 (15.5)  
25-34 437 231 (26.6) 206 (27.7)  
35-44 453 245 (28.2) 208 (28.0)  
45-54 229 125 (14.4) 104 (14.0)  
55+ 178 107 (12.3) 71 (9.6)  
Not recorded 77 51 (5.9) 26 (3.5)  
Type of TB patient:     
New 1,505 805 (92.6) 700 (94.2) < 0.001 
Retreatment 54 16 (1.8) 38 (5.1)  
Not recorded 53 48 (5.5) 5 (< 1)  
Site of TB     
Pulmonary TB 1,494 769 (88.5) 725 (97.6) < 0.001 
Extra-pulmonary TB 5 3 (< 1) 2 (< 1)  
Not recorded 113 97 (11.2) 16 (2.2)  
HIV and ART status     
HIV-ve 262 84 (9.7) 178 (24.0) < 0.001 
HIV +ve, on ART 526 219 (25.2) 307 (41.3)  
HIV +ve, ART status unknown 178 92 (10.6) 86 (11.6)  
HIV status unknown 646 474 (54.6) 172 (23.2)  
TB = Tuberculosis; CDST = Culture and Drug Susceptibility Test; Rif +ve = Rifampicin resistance detected, Rif -ve = Rifampicin sensitive; HIV- Human 
immunodeficiency virus; ART- Antiretroviral therapy. 
 
